tirzepatide semaglutide head to head vs. Semaglutide: What the Head-to-Head Trial Showed — Shreveport Direct Care First head-to-head study in people

Food and Drug Administration for the treatment of obesity and type 2 diabetes in 2022

Get my personal tips for navigating weekly injections and staying hydrated

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase

Understanding these differences is crucial for choosing the right path for your individual needs.

Understand how they may help you lose weight while also considering potential risks.

Clinical Evidence Semaglutide has demonstrated significant weight reduction in large-scale clinical trials when combined with reduced-calorie diet and increased physical activity